The global nasal polyp treatment market has a CAGR of 5%. Merck, Sanofi, etc. participate in the competition

CompilationFan Dongdong

A few days ago, Transparent Market Research (TMR) released the latest market analysis report on the nasal polyp treatment market during the forecast period from 2019 to 2027.

Due to the increasing number of elderly people suffering from chronic rhinosinusitis (CRSwNP) of nasal polyps, otolaryngologists and surgeons in developed areas are using more frequent minimally invasive surgery, and the treatment channels for nasal polyps are becoming more abundant.

North America accounted for a major share in the global nasal polyp treatment market in 2018.

Global CRSwNP prevalence drives market growth

TMR predicts that from 2019 to 2027, the prevalence of inflammatory and respiratory diseases such as CRSwNP, asthma, nasal polyps and allergic rhinitis will increase the global nasal polyp treatment market.

Chronic rhinosinusitis (CRS) is a rhinitis disease that affects the tissues inside the nasal cavity and paranasal sinuses, causing symptoms to last from 8 weeks to 12 weeks or longer.

Therefore, the increasing prevalence and treatment burden of chronic respiratory diseases such as CRSwNP will drive the market demand for treatments and therapies by patients.

Existing treatment methods

In terms of treatment, the global nasal polyp treatment market can be divided into drug therapy and surgery.

The field of drug therapy dominated the global nasal polyp treatment market in 2018, and this trend is expected to continue during the forecast period.

Intranasal steroid sprays, systemic and oral corticosteroids, nasal irrigation saline, and antibiotics are widely used to treat CRSwNP patients with nasal polyps.

Hospitals are expected to become the growth point of surgical treatment

Surgical treatments for nasal polyps include: polypectomy and functional endoscopic sinus surgery (FESS), which are mainly performed in ambulatory surgery centers, hospitals and specialist clinics.

TMR believes that the growth of this sector is attributable to the increased availability of professional nursing services in hospitals and the emergence of qualified healthcare professionals in hospitals.

North America has outstanding performance and the Asia-Pacific region is an incremental opportunity for the future

In terms of regions, the global nasal polyp treatment market has been subdivided into North America, Europe, Latin America, Asia Pacific, and the Middle East and Africa.

It is expected that the nasal polyp treatment market in the Asia-Pacific region will grow rapidly in the next few years.

Market growth strategies of major pharmaceutical manufacturers of nasal polyps

The major players operating in the global nasal polyp treatment market are Merck, Sanofi, Pfizer, GlaxoSmithKline, Novartis, as well as Intersect ENT and OptiNose US, Inc.

In April 2018, Intersect ENT announced the launch of SINUVA sinus implants in the United States.

Four months after obtaining US FDA approval, Sanofi and its partner Regeneron announced in October 2019 that the European Commission (EC) had approved Dupixent (dupilumab) as an add-on therapy for intranasal corticosteroids.

In April 2020, GlaxoSmithKline announced that its anti-IL-5 monoclonal antibody Nucala (mepolizumab) has reached the test in the key phase 3 clinical trial SYNAPSE for the treatment of patients with chronic rhinosinusitis (CRSwNP) with nasal polyps The primary endpoint and critical secondary endpoint.

In December 2020, the Xolair (omalizumab) pre-filled syringe jointly developed by Roche and Novartis was approved for the treatment of nasal polyps, as an add-on therapy to intranasal corticosteroids (INC), for the treatment of inadequate control with INC.
Adult patients (≥18 years of age) with severe chronic rhinosinusitis with nasal polyps (CRSwNP).

In May 2021, OptiNose announced the financial report for the first quarter of fiscal year 2021.
The net profit attributable to common shareholders of the parent company was US$26,053, a year-on-year increase of 9.
71%; operating income was US$11.
96 million, a year-on-year increase of 69.
36%.
The main product of OptiNose is XHANCE nasal spray, which uses a unique breathing exhalation system and is an effective anti-inflammatory corticosteroid hormone for the treatment of chronic sinusitis and nasal polyps.

Reference source: Nasal Polyps Treatment Market: Pharmacological therapies segment dominated the global market